🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "huge turning point" in the fight against superbug strains of the pathogen, according to researchers.

An International Public Health Issue

Cases of gonorrhoea are on the rise worldwide, with estimates suggesting over 82 million new cases per year. Especially elevated rates are seen in the African continent and nations within the WHO's designated area, which includes Mongolia and China to New Zealand. Across England, cases have reached a all-time high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely development in the context of rising global incidence, the spread of superbugs and the extremely scarce therapeutic options presently on offer.”

Medical experts are particularly alarmed about the rise in antibiotic-resistant strains. The global health body has classified it as a "priority pathogen". A tracking program showed that resistance to key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Treatment Options Receive Approval

Zoliflodacin, marketed under the name a brand name, was approved by the US FDA in recent days for treating gonorrhoea. This disease can lead to significant complications, including infertility. Scientists anticipate that focused deployment of this new drug will help slow the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GSK, also received approval in concurrent days. This drug, which is employed against urinary tract infections, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin emerged from a new, not-for-profit approach for antibiotic development. The charitable organization GARDP collaborated with the pharmaceutical company Innoviva to develop it.

“This milestone represents a huge turning point in the therapy of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Testing Results and Worldwide Availability

Based on data detailed in a major medical journal, the new drug successfully treated more than 90% of uncomplicated infections. This puts it on an equal footing with the existing first-line therapy, which uses two antibiotics. The trial included nearly 1,000 participants from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, the non-profit has the ability to license and sell the drug in many low-income and middle-income countries.

Doctors directly involved have shared optimism. Having a easy-to-administer therapy like this is hailed as a "game-changer" for gonorrhoea control. This is considered vital to alleviate the strain of the infection for patients and to halt the transmission of extremely resistant gonorrhoea around the world.